RPG Life Sciences Ltd
NSE: RPGLIFE BSE: 532983
₹2300.20
(0.01%)
Wed, 27 May 2026, 05:42 pm
Market Cap37.98B
PE Ratio33.03
Dividend0.87
Health Technology
Pharmaceuticals: Major
24.5KRPG Life Sciences Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (7.3x coverage).
- RPG Life Sciences's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- RPG Life Sciences's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- RPG Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- RPG Life Sciences is profitable, therefore cash runway is not a concern.
- RPG Life Sciences is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (1251.1%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 31.4x debt.
- RPG Life Sciences's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (26.4% vs 2.3% today).
- Interest payments on debt are well covered by earnings (EBIT is 24.5x coverage).
- RPG Life Sciences's level of debt (2.3%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the RPG Life Sciences board of directors is about average.
- Yugal Kishor's compensation has been consistent with company performance over the past year, both up more than 20%.
- The tenure for the RPG Life Sciences management team is about average.
- Yugal Kishor's remuneration is higher than average for companies of similar size in India.
misc
- RPG Life Sciences is not covered by any analysts.
- RPG Life Sciences has significant price volatility in the past 3 months.
past
- RPG Life Sciences's 1-year earnings growth exceeds its 5-year average (166.6% vs 18.7%)
- RPG Life Sciences's year on year earnings growth rate has been positive over the past 5 years.
- RPG Life Sciences used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- RPG Life Sciences has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- RPG Life Sciences's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (166.6% vs 22.7%).
- RPG Life Sciences has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- RPG Life Sciences is good value based on earnings compared to the IN Pharmaceuticals industry average.
- RPGLIFE outperformed the Market in India which returned -14.5% over the past year.
- NSEI:RPGLIFE is up 10.5% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:RPGLIFE is up 10.5% outperforming the market in India which returned 8% over the past month.
- RPG Life Sciences's share price is below the future cash flow value, but not at a moderate discount (< 20%).
- RPG Life Sciences's share price is below the future cash flow value, but not at a substantial discount (< 40%).
- RPG Life Sciences is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- RPG Life Sciences is overvalued based on earnings compared to the India market.
- RPGLIFE underperformed the Pharmaceuticals industry which returned 26.7% over the past year.